



Rexahn Pharmaceuticals, Inc.  
Investor Relations Department  
15245 Shady Grove Road, Suite  
455  
Rockville, MD 20850  
United States

Visit IR website [↗](#)  
Sign-up for email alerts [↗](#)

**AMEX: RNN**

Last Trade:	1.65
Trade Time:	8:00 PM ET 04/20/18
Change:	0.00 (0.000%)
Day Range	1.59 - 1.70
52-Week Range	1.42 - 4.84
Volume	204,268

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and Supinoxin™ (RX-5902) and a robust pipeline of preclinical compounds to treat multiple types of cancer.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*03/13/18*

[Rexahn Pharmaceuticals to Present at Two Upcoming Conferences](#)

*03/12/18*

[Rexahn Pharmaceuticals Reports Full Year 2017 Financial Results](#)

*02/12/18*

[Rexahn Reports Data from the Ongoing Phase 2a Clinical Trial of RX-3117 in Advanced Bladder Cancer at the American Society of Clinical Oncology Genitourinary Cancers \(ASCO GU\) 2018 Annual Meeting](#)

*02/08/18*

[Rexahn Pharmaceuticals Announces Collaboration with Zhejiang Haichang Biotechnology Co., Ltd. for the Development of RX-0201 \(Archexin®\) for the treatment of Hepatocellular Carcinoma](#)

*02/05/18*

[Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Genitourinary Cancers \(ASCO GU\) 2018 Annual Meeting](#)

## Financials [\[ View all \]](#)

[Fourth Quarter Financial Results](#)

*03/09/18*

[Annual Report \(10-K\)](#)

*02/24/17*

[Proxy Statement \(DEF 14A\)](#)

*11/03/17*

[Quarterly Report \(10-Q\)](#)

*08/04/17*

[Quarterly Report \(10-Q\)](#)

*05/03/17*

[Quarterly Report \(10-Q\)](#)